Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093549 | 0.87 | PDE2A (0.53) | PDE2ASLC7A5HDAC1HDAC3HDAC2 | |
| SCHEMBL19506249 | 0.86 | PDE2A (0.45) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL19505338 | 0.84 | PDE2A (0.44) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL19506250 | 0.84 | PDE2A (0.44) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL19506041 | 0.84 | PDE2A (0.46) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL19505971 | 0.83 | PDE2A (0.43) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL19506288 | 0.83 | NR1I2 (0.51) | PDE2ASLC2A1SLC7A5HDAC1HDAC3 | |
| SCHEMBL1042394 | 0.83 | PDE2A (0.45) | PDE2ASLC7A5HDAC1HDAC3HDAC2 | |
| SCHEMBL1042393 | 0.83 | PDE2A (0.45) | PDE2ASLC7A5HDAC1HDAC3HDAC2 | |
| SCHEMBL2093775 | 0.83 | PDE2A (0.45) | PDE2ASLC7A5HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002284-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2022-01-06 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180079784-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | ST.JUDE CHILDREN'S RESEARCH HOSPITAL | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170304270-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170304271-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | ABCG2, ABCC1, PNPO | PDE2A 440/4885SLC2A1 2455/4885SLC7A5 19/4885 |
| US-20180079784-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | CLPP, PEPD, DNPEP | PDE2A 1799/4885SLC2A1 2379/4885SLC7A5 2634/4885 |
| US-20220002284-A1 | PESTICIDAL COMPOUNDS | NIT2, PNMT, THOP1 | PDE2A 347/4885SLC2A1 3509/4885SLC7A5 1877/4885 |
| US-20170304271-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | FXR1, SLC10A1, NR1H4 | PDE2A 1064/4885SLC2A1 905/4885SLC7A5 1483/4885 |
| US-20180193343-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PRKG1, PDE2A | PDE2A 3/4885SLC2A1 1760/4885SLC7A5 2644/4885 |
| US-20170304270-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, FXR1, NR1H4 | PDE2A 1025/4885SLC2A1 848/4885SLC7A5 1412/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | PDE2A 858/4885SLC2A1 1906/4885SLC7A5 3102/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | PDE2A 858/4885SLC2A1 1906/4885SLC7A5 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.